JP2024540839A5 - - Google Patents
Info
- Publication number
- JP2024540839A5 JP2024540839A5 JP2024520702A JP2024520702A JP2024540839A5 JP 2024540839 A5 JP2024540839 A5 JP 2024540839A5 JP 2024520702 A JP2024520702 A JP 2024520702A JP 2024520702 A JP2024520702 A JP 2024520702A JP 2024540839 A5 JP2024540839 A5 JP 2024540839A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- pharmaceutical composition
- alkyl
- kras
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163252561P | 2021-10-05 | 2021-10-05 | |
| US63/252,561 | 2021-10-05 | ||
| PCT/US2022/045623 WO2023059598A1 (en) | 2021-10-05 | 2022-10-04 | Combination therapies of kras g12d inhibitors with shp-2 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540839A JP2024540839A (ja) | 2024-11-06 |
| JP2024540839A5 true JP2024540839A5 (enExample) | 2025-10-10 |
Family
ID=85803689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024520702A Pending JP2024540839A (ja) | 2021-10-05 | 2022-10-04 | Ｋｒａｓ ｇ１２ｄ阻害剤とｓｈｐ－２阻害剤との併用療法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240423984A1 (enExample) |
| EP (1) | EP4412719A4 (enExample) |
| JP (1) | JP2024540839A (enExample) |
| KR (1) | KR20240073114A (enExample) |
| CN (1) | CN118401254A (enExample) |
| WO (1) | WO2023059598A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4436571A4 (en) * | 2021-11-24 | 2025-10-15 | Merck Sharp & Dohme Llc | SMALL MOLECULE INHIBITORS OF KRAS MUTATIONAL PROTEINS |
| EP4531846A1 (en) * | 2022-06-03 | 2025-04-09 | Verastem, Inc. | Combination therapy for treating abnormal cell growth |
| JP2025523101A (ja) * | 2022-07-12 | 2025-07-17 | メッドシャイン ディスカバリー インコーポレイテッド | ピペラジン架橋置換複素環ピリミジン系化合物 |
| CN121909197A (zh) * | 2023-08-22 | 2026-04-21 | 赛诺菲 | 2-(3,8-二氮杂双环[3.2.1]辛-3-基)-1,3,5-三嗪衍生物作为用于治疗癌症的kras g12d抑制剂 |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250114339A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor |
| US20250114346A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| WO2026080796A1 (en) * | 2024-10-11 | 2026-04-16 | Mirati Therapeutics, Inc. | Mrtx1133 capsule pharmaceutical compositions |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| MX2022002465A (es) | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| US20240139193A1 (en) | 2019-10-15 | 2024-05-02 | Amgen Inc. | Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers |
| WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| EP4225383A4 (en) | 2020-10-08 | 2024-12-11 | Kumquat Biosciences Inc. | MODULATORS OF CELLULAR PROLIFERATION AND THEIR USES |
| US20240166669A1 (en) * | 2021-03-05 | 2024-05-23 | Nikang Therapeutics, Inc. | Quinazoline amine derivatives as kras inhibitors |
| TW202317589A (zh) * | 2021-07-14 | 2023-05-01 | 美商尼坎醫療公司 | 作為ｋｒａｓ抑制劑的伸烷基衍生物 |
-
2022
- 2022-10-04 CN CN202280077626.5A patent/CN118401254A/zh active Pending
- 2022-10-04 KR KR1020247015004A patent/KR20240073114A/ko active Pending
- 2022-10-04 EP EP22879176.0A patent/EP4412719A4/en active Pending
- 2022-10-04 WO PCT/US2022/045623 patent/WO2023059598A1/en not_active Ceased
- 2022-10-04 JP JP2024520702A patent/JP2024540839A/ja active Pending
- 2022-10-04 US US18/694,921 patent/US20240423984A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024540839A5 (enExample) | ||
| JP2024537140A5 (enExample) | ||
| JP2022509724A5 (enExample) | ||
| JP2022548791A5 (enExample) | ||
| JP2022500381A5 (enExample) | ||
| JP2025000632A5 (enExample) | ||
| JP2022500385A5 (enExample) | ||
| JP2025000630A5 (enExample) | ||
| JP2024537139A5 (enExample) | ||
| JP2022500384A5 (enExample) | ||
| JP2022530866A5 (enExample) | ||
| JP2022535577A5 (enExample) | ||
| US9643977B2 (en) | Necroptosis inhibitors and methods of use therefor | |
| JP2019516718A5 (enExample) | ||
| JP2025000629A5 (enExample) | ||
| FI3849537T3 (fi) | Yhdistelmäterapioita | |
| JP2024537137A5 (enExample) | ||
| JP2004528379A5 (enExample) | ||
| JP2010536842A5 (enExample) | ||
| EA007933B1 (ru) | 2,4,5-тризамещенные производные тиазолила и их противовоспалительная активность | |
| JP2008500992A5 (enExample) | ||
| JP2009532452A5 (enExample) | ||
| JP2010515715A5 (enExample) | ||
| JP2013512903A5 (enExample) | ||
| CA2551737A1 (en) | Helix 12 directed steroidal pharmaceutical products |